Quantum Genomics Sa Stock Fundamentals
| ALQGC Stock | EUR 0.12 0.01 7.69% |
Quantum Genomics SA fundamentals help investors to digest information that contributes to Quantum Genomics' financial success or failures. It also enables traders to predict the movement of Quantum Stock. The fundamental analysis module provides a way to measure Quantum Genomics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Quantum Genomics stock.
Quantum |
Quantum Genomics SA Company Shares Outstanding Analysis
Quantum Genomics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Quantum Genomics Shares Outstanding | 34.53 M |
Most of Quantum Genomics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Quantum Genomics SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Quantum Genomics SA has 34.53 M of shares currently outstending. This is 80.87% lower than that of the Biotechnology sector and 67.69% lower than that of the Health Care industry. The shares outstanding for all France stocks is 93.96% higher than that of the company.
Quantum Genomics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Quantum Genomics's current stock value. Our valuation model uses many indicators to compare Quantum Genomics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Quantum Genomics competition to find correlations between indicators driving Quantum Genomics's intrinsic value. More Info.Quantum Genomics SA is number one stock in return on equity category among related companies. It is number one stock in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Quantum Genomics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Quantum Genomics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Quantum Genomics' earnings, one of the primary drivers of an investment's value.Quantum Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Quantum Genomics' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Quantum Genomics could also be used in its relative valuation, which is a method of valuing Quantum Genomics by comparing valuation metrics of similar companies.Quantum Genomics is currently under evaluation in shares outstanding category among related companies.
Quantum Fundamentals
| Return On Equity | -1.23 | |||
| Return On Asset | -0.48 | |||
| Operating Margin | (5.48) % | |||
| Current Valuation | (11.33 M) | |||
| Shares Outstanding | 34.53 M | |||
| Shares Owned By Insiders | 9.18 % | |||
| Shares Owned By Institutions | 3.69 % | |||
| Price To Earning | (5.10) X | |||
| Price To Book | 0.32 X | |||
| Price To Sales | 1.07 X | |||
| Revenue | 116.21 K | |||
| Gross Profit | (12.47 M) | |||
| EBITDA | (18.94 M) | |||
| Net Income | (17.36 M) | |||
| Cash And Equivalents | 5.01 M | |||
| Cash Per Share | 0.89 X | |||
| Total Debt | 283.69 K | |||
| Current Ratio | 3.36 X | |||
| Book Value Per Share | 0.44 X | |||
| Cash Flow From Operations | (17.02 M) | |||
| Earnings Per Share | (0.73) X | |||
| Target Price | 8.8 | |||
| Beta | 0.27 | |||
| Market Capitalization | 5.65 M | |||
| Total Asset | 22.59 M | |||
| Z Score | 11.4 | |||
| Net Asset | 22.59 M |
About Quantum Genomics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Quantum Genomics SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Quantum Genomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Quantum Genomics SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Quantum Genomics Socit Anonyme, a biopharmaceutical company, develops drugs to treat cardiovascular diseases. It is also developing QGC011 that is in pre-clinical phase to treat hypertension with combination therapy and QGC006 to optimize the treatment of hypertension with a monotherapy drug. QUANTUM GENOMICS operates under Pharmaceuticals And Biosciences classification in France and is traded on Paris Stock Exchange. It employs 13 people.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Quantum Genomics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Quantum Genomics' short interest history, or implied volatility extrapolated from Quantum Genomics options trading.
Pair Trading with Quantum Genomics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Quantum Genomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Quantum Genomics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Quantum Genomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Quantum Genomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Quantum Genomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Quantum Genomics SA to buy it.
The correlation of Quantum Genomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Quantum Genomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Quantum Genomics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Quantum Genomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Quantum Genomics SA. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Quantum Genomics information on this page should be used as a complementary analysis to other Quantum Genomics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Complementary Tools for Quantum Stock analysis
When running Quantum Genomics' price analysis, check to measure Quantum Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Quantum Genomics is operating at the current time. Most of Quantum Genomics' value examination focuses on studying past and present price action to predict the probability of Quantum Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Quantum Genomics' price. Additionally, you may evaluate how the addition of Quantum Genomics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |